Naike Casagrande

Centro di Riferimento Oncologico — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.3kcitations51works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Lipids, and Metabolism(13), Nanoparticle-Based Drug Delivery(10), Metal complexes synthesis and properties(10), Lymphoma Diagnosis and Treatment(9), Estrogen and related hormone effects(8)

Publications51 total

Behind the scenes: how the <scp>EMILIN</scp> /Multimerin family shapes the cancer landscape
FEBS Journal·2025Open Access
Innovative Stem Cell Assisted Lipotransfer Approach for Breast Reconstruction in cancer Patients: Efficacy and Safety of the LIPO MULTI-SVF Study
Stem Cell Reviews and Reports·2025· 1 citedOpen Access
BOC.02.6 MULTIMERIN-2 LOSS IMPINGES ON VASCULAR STABILITY FAVORING COLORECTAL CANCER CELL DISSEMINATION
Digestive and Liver Disease·2025
In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin
Biomedicine & Pharmacotherapy·2024· 11 citedOpen Access
In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869
Cells·2023· 4 citedOpen Access
Overcome Resistance in Doxorubicin-Adapted Hodgkin Lymphoma Cells With Acquired Multidrug Resistance and Improved Immunosuppressive Abilities
Preprints.org·2023· 1 citedOpen Access
Dinuclear gold(I) complexes based on carbene and diphosphane ligands: bis[2-(dicyclohexylphosphano)ethyl]amine complex inhibits the proteasome activity, decreases stem cell markers and spheroid viability in lung cancer cells
JBIC Journal of Biological Inorganic Chemistry·2023· 5 cited
Figure S2 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Conflict of Interest Form Aldinucci D from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Figure S3 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Figure S2 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Data from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Figure S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Supplementary materials from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Table S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Figure S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Conflict of Interest Form Aldinucci D from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Table S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Table S2 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
Data from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Donatella Aldinucci(46), Cinzia Borghese(41), Alfonso Colombatti(25), Marta Celegato(24), Maurizio Mongiat(23), Giuseppe Corona(7), Anvarhusein A. Isab(7), Adam A. A. Sulaiman(7), Muhammad Altaf(6), Khalid H. Omer(3), Saleh Altuwaijri(3), Abdel‐Nasser Kawde(2), Roberto Larcher(2), Francesco Agostini(2), Cristina Durante(2), M. Mazzucato(2), Dolores Fregona(2), Luca Ronconi(2), Vincenzo Canzonieri(2), Antonino Carbone(2)